在克服前列腺癌的免疫疗法抗药性方面,Corvus Petrographes's ciforadenant表现出有希望。 Corvus Pharmaceuticals' ciforadenant shows promise in overcoming immunotherapy resistance in prostate cancer.

Corvus Pharmaceuticals 提供的新数据表明，ciforadenant（一种靶向腺苷 A2A 受体的药物）可以帮助克服转移性去势抵抗性前列腺癌对免疫治疗的耐药性。 Corvus Pharmaceuticals presented new data suggesting that ciforadenant, a drug that targets adenosine A2A receptors, could help overcome resistance to immunotherapy in metastatic castration-resistant prostate cancer. 在SITC年会上提出的数据显示, 甲降低了免疫抑制, 增强了抗PD1治疗的有效性. The data, presented at the SITC Annual Meeting, showed that ciforadenant reduced immunosuppression and enhanced the effectiveness of anti-PD1 therapy. 目前,该药物正在临床试验中。 The drug is currently in clinical trials.